




RealRate

PHARMACEUTICAL 2014

Lexicon Pharmaceuticals INC
Rank 117 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lexicon Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexicon Pharmaceuticals INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Lexicon Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 261%, being 19% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	134,554
Cost of Goods Sold	0
Intangible Assets	44,543
Liabilities, Current	19,294
Liabilities, Non-Current	52,553
Other Assets	53,701
Other Compr. Net Income	-21
Other Expenses	-239
Other Liabilities	32,150
Other Net Income	216
Other Revenues	2,222
Property and Equipment	41,362
Research and Development	89,682
Selling, General and Administrative Expense	17,121

Output Variable	Value in 1000 USD
Assets	274,160
Liabilities	103,997
Expenses	106,564
Revenues	2,222
Stockholders Equity	170,163
Net Income	-104,126
Comprehensive Net Income	-104,136
BaseVar	243,590
ECR before Limited Liability	141%
Economic Capital Ratio	261%